Wednesday, October 31, 2018 5:46:29 AM
From what I can see, we're looking at:
1. NASH Phase II results, about Q1 2019
2. RA Phase III results, maybe Q2 2019 for topline, then Q4 for finalisation of all results
3. Psoriasis Phase III results, about Q2 2019 for topline, Q1 2020 for finalisation of all results
In the meantime much money will be needed. But I like the products and the science makes sense.
https://clinicaltrials.gov/ct2/results?cond=&term=can-fite&cntry=&state=&city=&dist=
1. NASH Phase II results, about Q1 2019
2. RA Phase III results, maybe Q2 2019 for topline, then Q4 for finalisation of all results
3. Psoriasis Phase III results, about Q2 2019 for topline, Q1 2020 for finalisation of all results
In the meantime much money will be needed. But I like the products and the science makes sense.
https://clinicaltrials.gov/ct2/results?cond=&term=can-fite&cntry=&state=&city=&dist=
Recent CANF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2026 08:30:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 11:02:09 AM
- Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market • GlobeNewswire Inc. • 05/18/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2026 11:05:55 AM
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy • GlobeNewswire Inc. • 05/13/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 12:34:19 PM
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months • GlobeNewswire Inc. • 04/30/2026 12:31:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 08:15:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 11:59:42 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/06/2026 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/03/2026 09:07:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:22:12 AM
- Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 • GlobeNewswire Inc. • 03/30/2026 11:20:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/26/2026 02:05:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 01:29:33 PM
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient • GlobeNewswire Inc. • 03/26/2026 01:27:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/17/2026 11:50:36 AM
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance • GlobeNewswire Inc. • 03/17/2026 11:47:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:30:01 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/05/2026 12:31:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:29:04 PM
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds • GlobeNewswire Inc. • 03/04/2026 03:25:41 PM
